The goal of this exploratory study was to identify potential predictive biomarkers in the mammalian target of rapamycin ( mTOR ) complex @ ( mTORC@ ) activation pathway using primary tumor samples collected during the phase II tamoxifen plus everolimus ( TAMRAD ) trial .